Brandes International ETF (BINV)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund is an actively managed exchange-traded fund (“ETF”) that seeks to attain its investment objective by investing primarily in equity securities of foreign companies. The fund typically invests in foreign companies with market capitalizations (market value of publicly traded equity securities) greater than $5 billion at the time of purchase.

OfficialStocktwitsUser
OfficialStocktwitsUser May. 12 at 1:21 AM
$BINV RSI: 51.15, MACD: 0.2358 Vol: 0.62, MA20: 42.72, MA50: 41.96 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 4 at 6:13 PM
$BINV Current Stock Price: $42.69
0 · Reply
PenkeInvesting
PenkeInvesting May. 20 at 10:32 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of 2023 ETF Series Trust - Brandes International ETF. Is that bullish or bearish? $BINV #RsiOverbought #BATS
0 · Reply
PenkeInvesting
PenkeInvesting Mar. 19 at 4:18 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of 2023 ETF Series Trust - Brandes International ETF. Is that bullish or bearish? $BINV #RsiOverbought #BATS
0 · Reply
Stock_Titan
Stock_Titan Mar. 5 at 12:00 PM
$CASI $BINV CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China https://www.stocktitan.net/news/CASI/casi-pharmaceuticals-report-positive-interim-phase-1-data-for-bi-4imgphl23c8v.html
0 · Reply
Stock_Titan
Stock_Titan Oct. 10 at 5:30 AM
$BINV Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab) https://www.stocktitan.net/news/BINV/transgene-and-bio-invent-first-patient-treated-in-part-b-of-phase-i-i0pfgkvgmowg.html
0 · Reply
Latest News on BINV
Why Goldman Sachs is helping its clients launch ETFs

Apr 1, 2024, 6:46 PM EDT - 2 years ago

Why Goldman Sachs is helping its clients launch ETFs

BSMC BUSA EAGL QLTY

Hedge funds, family offices among those turning to Goldman Sachs ETF Accelerator

Oct 9, 2023, 2:22 PM EDT - 2 years ago

Hedge funds, family offices among those turning to Goldman Sachs ETF Accelerator

BSMC BUSA

OfficialStocktwitsUser
OfficialStocktwitsUser May. 12 at 1:21 AM
$BINV RSI: 51.15, MACD: 0.2358 Vol: 0.62, MA20: 42.72, MA50: 41.96 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 4 at 6:13 PM
$BINV Current Stock Price: $42.69
0 · Reply
PenkeInvesting
PenkeInvesting May. 20 at 10:32 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of 2023 ETF Series Trust - Brandes International ETF. Is that bullish or bearish? $BINV #RsiOverbought #BATS
0 · Reply
PenkeInvesting
PenkeInvesting Mar. 19 at 4:18 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of 2023 ETF Series Trust - Brandes International ETF. Is that bullish or bearish? $BINV #RsiOverbought #BATS
0 · Reply
Stock_Titan
Stock_Titan Mar. 5 at 12:00 PM
$CASI $BINV CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China https://www.stocktitan.net/news/CASI/casi-pharmaceuticals-report-positive-interim-phase-1-data-for-bi-4imgphl23c8v.html
0 · Reply
Stock_Titan
Stock_Titan Oct. 10 at 5:30 AM
$BINV Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab) https://www.stocktitan.net/news/BINV/transgene-and-bio-invent-first-patient-treated-in-part-b-of-phase-i-i0pfgkvgmowg.html
0 · Reply